Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies

Patent metadata

Field	Value
Publication number	US-10358490-B2
Application number	US-201715694374-A
Country	US
Kind code	B2
Filing date	Sep 1, 2017
Priority date	May 22, 2012
Publication date	Jul 23, 2019
Grant date	Jul 23, 2019

Abstract

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

First claim

What is claimed is:

1. A method of inhibiting inflammation in a human in need of such treatment comprising administering to the human a therapeutically effective amount of a bispecific antibody comprising an IL-17A/F binding entity and an IL-23 binding entity;
wherein the IL-23 binding entity comprises two pairs of immunoglobulin chains, each pair having one light and one heavy chain; wherein the light chain variable domain comprises a CDR1 having the amino acid sequence of SEQ ID NO:22, a CDR2 having the amino acid sequence of SEQ ID NO:23, and a CDR3 having the sequence of SEQ ID NO:24; and the heavy chain variable domain comprises a CDR1 having the amino acid sequence of SEQ ID NO:19, a CDR2 having the amino acid sequence of SEQ ID NO:20, and a CDR3 having the amino acid sequence of SEQ ID NO:21;
wherein the IL-17A/F binding entity comprises two Fab fragments linked to the C-terminus of the heavy chain of the IL-23 binding entity; wherein the light chain variable domain of the Fab of the IL-17A/F binding entity comprises a CDR1 having the amino acid sequence of SEQ ID NO:22, a CDR2 having the amino acid sequence of SEQ ID NO:23, and a CDR3 having the amino acid sequence of SEQ ID NO:24, and wherein the heavy chain variable domain of the Fab of the IL-17A/F binding entity comprises a CDR1 having the amino acid sequence of SEQ ID NO:25, a CDR2 having the amino acid sequence of SEQ ID NO:26, and a CDR3 having the amino acid sequence of SEQ ID NO:27; and
wherein after administration the inflammation is reduced.

2. The method of claim 1 , wherein the light chains of the Fab of the IL-17A/F binding entity and the IL-23 binding entity comprise a variable domain comprising the amino acid sequence of SEQ ID NO:9.

3. The method of claim 2 , wherein the light chains of the Fab of the IL-17A/F binding entity and the IL-23 binding entity comprise a constant domain comprising the amino acid sequence of SEQ ID NO:10.

4. The method of claim 3 , wherein the heavy chain variable domain of the IL-23 binding entity comprises the amino acid sequence of SEQ ID NO:7.

5. The method of claim 4 , wherein the heavy chain constant domain of the IL-23 binding entity comprises the amino acid sequence of SEQ ID NO:8 or amino acid residues 1-326 of SEQ ID NO:8.

6. The method of claim 5 , wherein the light chain of the Fab of the IL-17A/F binding entity and the IL-23 binding entity comprises the amino acid sequence of SEQ ID NO:17.

7. The method of claim 6 , wherein the heavy chain variable domain of the Fab of the IL-17A/F binding entity comprises the amino acid sequence of SEQ ID NO:13.

8. The method of claim 7 , wherein the heavy chain CH1 of the Fab of the IL-17A/F binding entity comprises the amino acid sequence of SEQ ID NO:15.

9. The method of claim 1 , wherein the heavy chain variable domain of the IL-23 binding entity comprises the amino acid sequence of SEQ ID NO:7.

10. The method of claim 1 , wherein the light chain of the Fab of the IL-17A/F binding entity and the IL-23 binding entity comprises the amino acid sequence of SEQ ID NO:17.

11. The method of claim 10 , wherein the heavy chain of the bispecific antibody comprises the amino acid sequence of SEQ ID NO:74.

12. The method of claim 1 , wherein the light chain of the Fab of the IL-17A/F binding entity and the IL-23 binding entity comprises the amino acid sequence of SEQ ID NO:17; and wherein the heavy chain of the bispecific antibody comprises the amino acid sequence of SEQ ID NO:74.

13. The method of claim 1 , wherein the isotype of the heavy chain constant domain of the IL-23 binding entity is IgG.

14. The method of claim 13 , wherein the isotype of the heavy chain constant domain of the IL-23 binding entity is IgG1 or IgG4.

15. The method of claim 13 , wherein the isotype of the heavy chain constant domain of the IL-23 binding entity is IgG4.

16. The method of claim 1 , wherein the inflammation is associated with multiple sclerosis (MS), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, atopic dermatitis, contact dermatitis, systemic sclerosis, systemic lupus erythematosus (SLE), antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), giant cell arteritis, colitis, endotoxemia, arthritis, rheumatoid arthritis (RA), osteoarthritis, Sjögren's syndrome, psoriasis, or psoriatic arthritis.

17. A method of inhibiting inflammation in a human in need of such treatment comprising administering to the human a therapeutically effective amount of a bispecific antibody comprising an IL-17A/F binding entity and an IL-23 binding entity, wherein the IL-23 binding entity comprises two pairs of immunoglobulin chains, each pair having one light and one heavy chain;
wherein the light chain of the Fab of the IL-17A/F binding entity and the IL-23 binding entity comprises the amino acid sequence of SEQ ID NO:7;
wherein the heavy chain of the bispecific antibody, comprises the amino acid sequence of SEQ ID NO:74; and
wherein after administration the inflammation is reduced.

18. The method of claim 17 , wherein the inflammation is associated with multiple sclerosis (MS), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, atopic dermatitis, contact dermatitis, systemic sclerosis, systemic lupus erythematosus (SLE), antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), giant cell arteritis, colitis, endotoxemia, arthritis, rheumatoid arthritis (RA), osteoarthritis, Sjögren's syndrome, psoriasis, or psoriatic arthritis.

Assignees

• Bristol Myers Squibb Co

Inventors

• Stevens Brenda L
• Witte Alison
• Rixon Mark W
• Cardarelli Josephine M
• Kempe Thomas D
• Presnell Scott R
• Srinivasan Mohan
• Wong Susan C
• Chen Guodong
• Wei Hui
• Krystek Stanley R
• Schneeweis Lumelle A
• Sheppard Paul O
• Chakraborty Indrani

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title